Respiratory News and Research

RSS

Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis

Aradigm Corporation announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE), a severe progressive respiratory disease for which there is currently no approved treatment in the U.S.

23 Mar 2011

Heart attack risk during sex is low: Study

According to the latest research from Tufts Medical Center, sexual intercourse, previously believed does increase the risk of a heart attack, but the risk is still small and only rises during and soon after the deed.

22 Mar 2011

Researchers launch free online Atlas of TB vaccination policies around the world

Tuberculosis continues to pose a major global health threat. Someone in the world is newly infected with TB bacteria every second. Every year, more than 9 million people develop active TB and it claims about 2 million lives.

22 Mar 2011

Survey: AR symptoms continue to impact patients' daily activities

Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.

22 Mar 2011

Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.

22 Mar 2011

Telecommunication engineer creates new child arrhythmias database

Ventricular Fibrillation is a series of intense and disordered contractions of the ventricles. In 40 % of respiratory arrests suffered outside a hospital, it was shown that the first cardiac rhythm corresponds to VF, and the only manner to combat it is with electric discharges provided by defibrillation.

22 Mar 2011

Researchers to develop house dust mite allergy vaccine that can cure asthma

Monash University researchers are working on a vaccine that could completely cure asthma brought on by house dust mite allergies.

22 Mar 2011

Innovative algorithm for AEDs distinguishes betweeen adult and child arrhythmias

Ventricular Fibrillation (VF) is a series of intense and disordered contractions of the ventricles (they are located in the lower part of the heart). In 40 % of respiratory arrests suffered outside a hospital, it was shown that the first cardiac rhythm corresponds to VF, and the only manner to combat it is with electric discharges provided by defibrillation. This

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

[UPDATE] Pediatric heart surgery unit of Royal Brompton faces closure

A London NHS trust would challenge proposals to end child heart surgery at the Royal Brompton Hospital. The Royal Brompton and Harefield NHS Foundation Trust added that this would mean the loss of other services, which could call into question its viability.

18 Mar 2011

Aerocrine acquires FENO technology platform and intellectual property from FILT

Aerocrine AB today announced the acquisition of key assets related to the measurement of FENO from German company FILT Lungen & Thoraxdiagnostik GmbH. FILT and Aerocrine will collaborate to develop new applications for airway inflammation monitoring and FILT will cease further commercialization of the NO VARIO® product.

18 Mar 2011

Cortex reports net loss of $0.01 per share for quarter ended December 31, 2010

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $984,000, or $0.01 per share for the quarter ended December 31, 2010 compared with a net loss of $1,599,000, or $0.02 per share for the corresponding prior year period.

18 Mar 2011

Rubini black elderberry extract can inhibit flu and respiratory tract infections

Historically, black elderberries were among the most regarded folk remedies for coughs, colds, and flu. Now modern science has authenticated these therapeutic properties. In February 2011, researchers at Justus-Liebig University in Geissen, Germany reported that a concentrated liquid extract of black elderberries, commercially available as Rubini - Elderberry Extract 3.2%, inhibited the growth of influenza A and B viruses and bacteria associated with upper respiratory tract infections.

18 Mar 2011

Englewood Hospital and Medical Center earns HealthGrades Patient Safety Excellence Award

Englewood Hospital and Medical Center was identified as a recipient of the 2011 HealthGrades Patient Safety Excellence Award, indicating that its patient safety ratings are in the top 5% of U.S. hospitals.

18 Mar 2011

JHUSON adds Harvey the Cardiopulmonary Simulator to simulation education

It's official: Harvey the Cardiopulmonary Simulator checked in for an extended stay at the Johns Hopkins University School of Nursing (JHUSON) last month. Harvey is the latest addition to the School's upgraded simulation laboratories and the newest member of the "Sim Fam." These life-like practice manikins, including Sim Man, Vital Sim Man,Noelle with newborn, and Sim Baby give nursing students the hands-on experience without the anxiety of working with actual human beings.

18 Mar 2011

CPF applauds new guidelines for treatment of idiopathic pulmonary fibrosis

The Coalition for Pulmonary Fibrosis (CPF) applauds the joint statement issued by the American Thoracic Society for the first evidence-based clinical guidelines for the treatment of idiopathic pulmonary fibrosis (IPF). The guidelines represent progress in understanding of the disease and a milestone for patients. The devastating and deadly disease also called simply "Pulmonary Fibrosis" or "PF" has no FDA approved treatment and no cure.

18 Mar 2011

Wash your hands? You may now approach the patient bed!

Each year patients in the U.S. get more than a million infections while in the hospital being treated for something else. The best way to prevent infection is to practice proper hand hygiene, according to the U.S. Centers for Disease Control and Prevention.

17 Mar 2011

TF3 consortium receives ECCH contract to provide RNTI

The TF3 consortium has been chosen to provide a Remote Telemonitoring Service to Northern Ireland which will support over 8,000 patients during the course of the contract.

17 Mar 2011

Cortex enters agreement with Biovail to regain AMPAKINE assets and rights

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., to regain the AMPAKINE® assets and rights related to respiratory depression.

16 Mar 2011

Researchers discover 3-D structure of key biological receptor

Researchers have solved the three-dimensional structure of a key biological receptor. The finding has the potential to speed drug discovery in many areas, from arthritis to respiratory disorders to wound healing, because it enables chemists to better examine and design molecules for use in experimental drugs.

16 Mar 2011